Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Epsilon Molecular Engineering Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, keeping the available prosecution activity within one examination setting.
ABBAS, SYED JARAR is the busiest examiner, with 1 pending matter. Counsel can concentrate on the claim record, the issues in the outstanding action, and the practices of the assigned biotechnology and pharmaceutical art unit. The profile shows no examiner or art-unit spread, so the prosecution strategy can remain focused on this individual matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, SYED JARAR | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571562 | RECEPTOR TYROSINE KINASE AGONIST, COMPOSITION FOR CELL CULTURE MEDIUM, AND UNDIFFERENTIATED MAINTENANCE COMPOSITION | ABBAS, SYED JARAR | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571562 | RECEPTOR TYROSINE KINASE AGONIST, COMPOSITION FOR CELL CULTURE MEDIUM, AND UNDIFFERENTIATED MAINTENANCE COMPOSITION | ABBAS, SYED JARAR | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEpsilon Molecular Engineering Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Syed Jarar Abbas has the most, with 1 of Epsilon Molecular Engineering Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
